Marvel Biosciences Inks LOI With Clinical Research Organization For Phase 1 MB-204 Trial
MT newswire2026/10/06 17:0401:04 PM EDT, 10/06/2026 (MT Newswires) -- Marvel Biosciences (MRVL.V) signed a letter of intent with a clinical research organization in the Asia-Pacific region to help develop its drug candidate MB-204 from the preclinical stage toward a Phase 1 first-in-human study, the company said on Tuesday. The Phase 1 program, to begin in the fourth quarter of this year, will establish the safety, tolerability and pharmacokinetic profile of MB-204 in humans. The data will inform the design of a subsequent multiple ascending dose (MAD) study, a statement said. MB-204 is a derivative of the anti-Parkinson's drug Istradefylline. According to the company, "a significant and growing body of scientific evidence suggests drugs that block the adenosine A2a receptor, such as MB-204, could be useful in treating other neurological diseases such as autism, depression and Alzheimer's Disease." Marvel Biosciences shares were last seen up CA$0.005 at CA$0.115 on the TSX Venture Exchange. Price: 0.12, Change: +0.01, Percent Change: +4.55
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Jensen Huang's influence surpasses that of Nvidia— and that's exactly the problem
Jensen Huang has been the key driving force behind the massive expansion of AI infrastructure, with his personal credibility and authoritative decision-making deeply embedded in the narrative of the global tech market’s rise over the past three years. Now, as scandals emerge, Nvidia’s trading team is expected to become more conservative and slow down external financing commitments, which undoubtedly worsens the situation for neoclouds already facing tight funding.
Deutsche Bank made significant Q3 purchases of midstream AI application stocks: the three major cloud giants saw increased holdings, with Palantir (PLTR.US) and Salesforce (CRM.US) also favored.
Deutsche Bank has submitted its third quarter 13F holdings report for the period ending September 30, 2026.
Crypto prices
More
